{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:48:32Z","timestamp":1784674112333,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rapid skin improvement is a key treatment goal of patients with moderate\u2010to\u2010severe psoriasis (PsO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare the speed of clinical improvement of approved biologics on the symptoms and signs of psoriasis assessed by patients using the validated Psoriasis Symptoms and Signs Diary (PSSD) through 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Psoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non\u2010interventional study that compares the effectiveness of anti\u2010interleukin (IL)\u201017A biologics versus other biologics, together with pairwise comparisons of ixekizumab versus five individual biologics in patients with PsO. Using the PSSD 7\u2010day recall period, patients assessed the symptoms (itch, skin tightness, burning, stinging and pain) and signs (dryness, cracking, scaling, shedding\/flaking, redness and bleeding) of their psoriasis (0\u201310). Symptom and sign summary scores (0\u2013100) are derived from the average of individual scores. Percentage change in summary scores and proportion of patients with clinically meaningful improvements (CMI) in PSSD summary and individual scores are evaluated weekly. Longitudinal PSSD data are reported as observed with treatment comparisons analysed using mixed model for repeated measures (MMRM) and generalized linear mixed models (GLMM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across cohorts and treatments, eligible patients (<jats:italic>n<\/jats:italic>\u2009=\u20091654) had comparable baseline PSSD scores. From Week 1, the anti\u2010IL\u201017A cohort achieved significantly larger score improvements in PSSD summary scores and a higher proportion of patients showed CMIs compared to the other biologics cohort through 12\u2009weeks. Lower PSSD scores were associated with a greater proportion of patients reporting their psoriasis as no longer impacting their quality\u2010of\u2010life (DLQI 0,1) and a high level of clinical response (PASI100). Results also indicate a relationship between an early CMI in PSSD score at Week 2 and PASI100 score at Week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with anti\u2010IL\u201017A biologics, particularly ixekizumab, resulted in rapid and sustained patient\u2010reported improvements in psoriasis symptoms and signs compared with other biologics in a real\u2010world setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19161","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:32:40Z","timestamp":1683354760000},"page":"1825-1840","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Speed of clinical improvement in the real\u2010world setting from patient\u2010reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12\u2009weeks"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"A.","family":"Reich","sequence":"first","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences Medical College of Rzeszow University  Rzeszow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"A.","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital Frankfurt  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-1545","authenticated-orcid":false,"given":"J.\u2010T.","family":"Maul","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Hospital of Z\u00fcrich and Faculty of Medicine University of Z\u00fcrich  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"R. B.","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research Inc. and Venderm Consulting  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"T.","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatology Research Unit Centro Hospitalar Universit\u00e1rio do Porto, University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brnabic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indiana Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-188X","authenticated-orcid":false,"given":"N.","family":"Haustrup","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indiana Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Reed","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indiana Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indiana Indianapolis USA"},{"name":"Department of Dermatology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Riedl","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1613-8"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0126-6"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15324"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13248"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2475530321999087"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00658-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14910"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1114567"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1364694"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdds.2015.07.004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00337-y"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18376"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02379-9"},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency.Psoriasis study of health outcomes \u2013 an international observational study of 3 year health outcomes in the biologic treatment of moderate to severe plaque psoriasis. In:Pharmacovigilance ENoCfPa editor.2018.https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=25115:EUPAS24207"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083509"},{"key":"e_1_2_10_22_1","first-page":"10010","article-title":"Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: a pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER\u20102 and UNCOVER\u20103)","volume":"74","author":"Leonardi C","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.431"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1084-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15226"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0396-z"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"e_1_2_10_29_1","first-page":"99","article-title":"Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: a systematic review","volume":"12","author":"Ruiter CC","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3700"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782317"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20387"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.028"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0851"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3617"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1515\/sjpain-2019-0158"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.066"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1528330"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:07:25Z","timestamp":1692950845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/jdv.19161"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19161","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"2022-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}